PMID- 8871047
OWN - NLM
STAT- MEDLINE
DCOM- 19970122
LR  - 20171116
IS  - 0904-1850 (Print)
IS  - 0904-1850 (Linking)
VI  - 22
DP  - 1996 Aug
TI  - Role of IL-4 in persistent IgE formation.
PG  - 67s-71s
AB  - Antigen-specific immunoglobulin E (IgE) responses against T-cell-dependent 
      antigens, like allergens, can only be generated by cognate interaction between 
      B-cells and T-helper (Th2) cells. This interaction is a prerequisite, donating 
      the two signals that are essential for IgE production: CD40 ligation with its 
      ligand gp39 and exposure to interleukin (IL)-4. Cytokine-mediated immunotherapy 
      geared at intervention in allergic diseases, therefore aims at inhibiting the 
      production or action of IL-4. In our view, based on two findings, this approach 
      is simplistic. The first is that anti-IL-4 based approach (by complex formation 
      between IL-4 and soluble IL-4 receptors or serum binding proteins) may actually 
      increase the persistence of IL-4 and its effects instead of inhibiting them. 
      Secondly, we have good evidence in mouse model systems that a period of exposure 
      to IL-4 will result in an increased population of gamma 1,epsilon-double positive 
      B-cells allowing an increased serum IgE level to persist for extensive periods of 
      time. These B-cells turn out to be partially independent of IL-4 for their IgE 
      formation. Moreover, these B-cells are partially independent of a cognate 
      interaction with T-cells for their subsequent IgE synthesis. Therefore, we 
      hypothesize that an approach geared solely at inhibiting IL-4 is not sufficient 
      for decreasing persistent IgE levels in allergic patients.
FAU - Savelkoul, H F
AU  - Savelkoul HF
AD  - Dept of Immunology, Erasmus University, Rotterdam, The Netherlands.
FAU - van Ommen, R
AU  - van Ommen R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur Respir J Suppl
JT  - The European respiratory journal. Supplement
JID - 8910681
RN  - 0 (CD40 Antigens)
RN  - 0 (Cytokines)
RN  - 207137-56-2 (Interleukin-4)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Animals
MH  - B-Lymphocytes/immunology
MH  - CD40 Antigens/immunology
MH  - Cell Communication
MH  - Cytokines/antagonists & inhibitors/biosynthesis/physiology
MH  - Hypersensitivity/*immunology
MH  - Immunoglobulin Class Switching
MH  - Immunoglobulin E/*biosynthesis
MH  - Immunotherapy
MH  - Interleukin-4/antagonists & inhibitors/*immunology/*physiology
MH  - Mice
MH  - Mice, Transgenic
MH  - Spleen/immunology
MH  - Th2 Cells/immunology
RF  - 32
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
PST - ppublish
SO  - Eur Respir J Suppl. 1996 Aug;22:67s-71s.